Have a feature idea you'd love to see implemented?
Let us know!
CRBU Caribou Biosciences Inc
Price (delayed)
$1.56
Market cap
$141.26M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.66
Enterprise value
$135.93M
Highlights
Caribou Biosciences's debt has decreased by 3% YoY
The revenue has dropped by 67% year-on-year and by 65% since the previous quarter
CRBU's gross profit has plunged by 67% YoY and by 65% from the previous quarter
Key stats
What are the main financial stats of CRBU
Market
Valuations
Earnings
Shares outstanding
90.55M
Market cap
$141.26M
Enterprise value
$135.93M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.5
Price to sales (P/S)
12.3
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
11.85
Revenue
$11.48M
Gross profit
$11.48M
Net income
-$148.12M
EBIT
-$147.93M
EBITDA
-$142.26M
Free cash flow
-$130.75M
Per share
Balance sheet
Liquidity
EPS
-$1.66
EPS diluted
-$1.66
Free cash flow per share
-$1.45
Book value per share
$3.11
Revenue per share
$0.13
TBVPS
$3.81
Total assets
$344.33M
Total liabilities
$63.13M
Debt
$26.64M
Equity
$281.2M
Working capital
$205.27M
Debt to equity
0.09
Current ratio
7.38
Quick ratio
7.15
Net debt/EBITDA
0.04
Margins
Efficiency
Dividend
EBITDA margin
-1,239.7%
Gross margin
100%
Net margin
-1,290.8%
Operating margin
-1,439.5%
Return on assets
-38.1%
Return on equity
-45.5%
Return on invested capital
-43.1%
Return on capital employed
-47.4%
Return on sales
-1,289.1%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
CRBU stock price
How has the Caribou Biosciences stock price performed over time
Intraday
0.65%
1 week
-16.58%
1 month
-18.32%
1 year
-71.32%
YTD
-1.89%
QTD
-1.89%
Financial performance
How have Caribou Biosciences's revenue and profit performed over time
Revenue
$11.48M
Gross profit
$11.48M
Operating income
-$165.18M
Net income
-$148.12M
Gross margin
100%
Net margin
-1,290.8%
The revenue has dropped by 67% year-on-year and by 65% since the previous quarter
CRBU's gross profit has plunged by 67% YoY and by 65% from the previous quarter
Caribou Biosciences's net income has shrunk by 57% YoY and by 20% QoQ
Caribou Biosciences's operating income has plunged by 51% YoY and by 17% from the previous quarter
Growth
What is Caribou Biosciences's growth rate over time
Valuation
What is Caribou Biosciences stock price valuation
P/E
N/A
P/B
0.5
P/S
12.3
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
11.85
Caribou Biosciences's EPS has decreased by 19% QoQ and by 10% YoY
The P/B is 50% less than the last 4 quarters average of 1.0
The equity fell by 29% YoY and by 9% QoQ
The revenue has dropped by 67% year-on-year and by 65% since the previous quarter
CRBU's P/S is 7% above its last 4 quarters average of 11.5
Efficiency
How efficient is Caribou Biosciences business performance
CRBU's ROA has dropped by 54% year-on-year and by 29% since the previous quarter
The ROE has plunged by 50% YoY and by 31% from the previous quarter
CRBU's return on invested capital is down by 42% year-on-year and by 24% since the previous quarter
Dividends
What is CRBU's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for CRBU.
Financial health
How did Caribou Biosciences financials performed over time
The quick ratio is down by 49% year-on-year and by 16% since the previous quarter
The current ratio has contracted by 48% YoY and by 16% from the previous quarter
Caribou Biosciences's debt is 91% less than its equity
The equity fell by 29% YoY and by 9% QoQ
Caribou Biosciences's debt to equity has increased by 29% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.